Cardiomyopathy due to drug and external agent
ICD-10 I42.7 is a billable code used to indicate a diagnosis of cardiomyopathy due to drug and external agent.
I42.7 refers to cardiomyopathy due to drug and external agents, a condition characterized by the deterioration of the heart muscle, which can lead to heart failure and other serious complications. This type of cardiomyopathy can result from various substances, including certain medications (e.g., chemotherapy agents, alcohol) and environmental toxins. Clinically, patients may present with symptoms such as fatigue, shortness of breath, palpitations, and edema. The anatomy involved primarily includes the myocardium, which is the muscular layer of the heart responsible for contraction. Disease progression can vary; some patients may experience acute symptoms following exposure to the offending agent, while others may develop chronic heart dysfunction over time. Diagnostic considerations include a thorough patient history to identify potential exposures, echocardiography to assess heart function, and possibly cardiac MRI or biopsy in complex cases. Laboratory tests may also be necessary to rule out other causes of heart failure.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
I42.7 covers cardiomyopathy resulting from exposure to drugs, including chemotherapeutic agents, alcohol, and certain recreational drugs, as well as environmental toxins. It is essential to document the specific agent involved to support the diagnosis.
I42.7 should be used when there is clear evidence of cardiomyopathy directly linked to a drug or external agent. If the cardiomyopathy is idiopathic or due to other causes, different codes should be considered.
Documentation should include a detailed patient history of drug use or exposure to toxins, clinical findings consistent with cardiomyopathy, and any relevant diagnostic tests that confirm the diagnosis.
